logo

Mirati Therapeutics, Inc. (MRTX)



Trade MRTX now with
  Date
  Headline
5/27/2022 10:50:34 AM Mirati Therapeutics Falls 34%
1/21/2022 10:02:01 AM Mirati Presents Positive Data With Investigational Adagrasib In Patients With KRASG12C-Mutated Gastrointestinal Cancers
11/22/2021 7:41:07 AM Mirati, Verastem Partner To Evaluate Adagrasib In Combination With VS-6766 In KRASG12C-Mutant Non-Small Cell Lung Cancer
11/17/2021 7:33:06 AM Mirati Therapeutics Submits INDA To U.S. FDA Of MRTX1719 To Treat MTAP-Deleted Cancers
11/10/2021 10:08:11 PM Mirati Therapeutics Prices Underwritten Public Offering Of 3.45 Mln Shares At $145.00/shr
9/20/2021 8:25:32 AM Mirati Therapeutics Announces Long-term Survival Results From Exploratory Analysis Of Sitravatinib Plus Nivolumab
9/20/2021 8:04:41 AM Mirati Therapeutics Appoints David Meek As CEO
9/20/2021 7:32:23 AM Mirati Therapeutics Announces Positive Topline Results From Phase 2 KRYSTAL-1 Study Evaluating Adagrasib